Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Luspatercept”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Looking for participantsNCT05181735
What this trial is testing

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Who this might be right for
MDSMyelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 150
Post-approval studies (Phase 4)UnknownNCT06006949
What this trial is testing

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Who this might be right for
Myelodysplastic Syndromes
Peking Union Medical College Hospital 62
Large-scale testing (Phase 3)Not Yet RecruitingNCT07636486
What this trial is testing

Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

Who this might be right for
LuspaterceptEpoetinPoor Erythroid Engraftment+1 more
Nanfang Hospital, Southern Medical University 90
Testing effectiveness (Phase 2)Looking for participantsNCT07096297
What this trial is testing

Luspatercept + Darbepoetin in MDS

Who this might be right for
MDS (Myelodysplastic Syndrome)
Yale University 60
Large-scale testing (Phase 3)Active Not RecruitingNCT03682536
What this trial is testing

Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Who this might be right for
Myelodysplastic Syndromes
Celgene 363
Early research (Phase 1)Looking for participantsNCT06670222
What this trial is testing

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Low-risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 24
Testing effectiveness (Phase 2)Study completedNCT05399732
What this trial is testing

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

Who this might be right for
Aplastic Anemia
Bing Han 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07331818
What this trial is testing

Luspatercept in Patients Affected With Rare Inherited Anemias

Who this might be right for
Hereditary Red Blood Cell Disorder (Disorder)
EuroBloodNet Association 45
Not applicableLooking for participantsNCT06073860
What this trial is testing

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

Who this might be right for
Myelodysplastic SyndromeBeta Thalassemia
Bristol-Myers Squibb 104
Large-scale testing (Phase 3)Study completedNCT02604433
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

Who this might be right for
Erythrocyte TransfusionBeta-Thalassemia
Celgene 336
Early research (Phase 1)Study completedNCT01432717
What this trial is testing

Study of ACE-536 in Healthy Postmenopausal Women

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 40
Not applicableActive Not RecruitingNCT06875219
What this trial is testing

To Evaluate Long- Term Safety and Efficacy of Luspatercept

Who this might be right for
Thalassemia Major
Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia 350
Testing effectiveness (Phase 2)Study completedNCT03342404
What this trial is testing

Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

Who this might be right for
Thalassemia
Celgene 145
Large-scale testing (Phase 3)Active Not RecruitingNCT05181592
What this trial is testing

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Who this might be right for
Myelodysplastic Syndromes
GWT-TUD GmbH 70
Large-scale testing (Phase 3)Not Yet RecruitingNCT06927232
What this trial is testing

AZA+Lus VS AZA Monotherapy in HR-MDS

Who this might be right for
Higher-risk Myelodysplastic Syndrome
Peking Union Medical College Hospital 86
Testing effectiveness (Phase 2)Study completedNCT01749514
What this trial is testing

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 116
Testing effectiveness (Phase 2)Looking for participantsNCT05384691
What this trial is testing

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 213
Not applicableStudy completedNCT06254781
What this trial is testing

Luspatercept in Metastatic AGCT of the Ovary

Who this might be right for
Adult Granulosa Cell Tumor of the Ovary
University Health Network, Toronto 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT05732961
What this trial is testing

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Who this might be right for
Myelodysplastic SyndromesMyeloproliferative NeoplasmAnemia
H. Lee Moffitt Cancer Center and Research Institute 6
Testing effectiveness (Phase 2)Study completedNCT04477850
What this trial is testing

Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Who this might be right for
Myelodysplastic Syndromes
Celgene 30
Load More Results